高危前列腺癌围手术期综合治疗专家共识(2023年版)  

Expert consensus on perioperative comprehensive treatment for high risk prostate cancer(2023 edition)

作　　者：中国抗癌协会男性生殖系统肿瘤专业委员会 叶定伟[2,3] 邹青 林国文[3] 徐子程 史本康[5] 邢金春[6] 朱绍兴[7] 何志嵩[8] 魏强[9] Society of Male Reproductive System Oncology,China Anti-Cancer Association;YE Dingwei;ZOU Qing

机构地区：[1]不详 [2]复旦大学附属肿瘤医院党委 [3]复旦大学附属肿瘤医院泌尿外科 [4]江苏省肿瘤医院泌尿外科 [5]山东大学齐鲁医院泌尿外科 [6]厦门大学附属第一医院泌尿外科 [7]福建医科大学附属协和医院泌尿外科 [8]北京大学第一医院泌尿外科 [9]四川大学华西医院泌尿外科

出　　处：《中国癌症杂志》2023年第12期1204-1216,共13页China Oncology

摘　　要：前列腺癌的发病率呈逐年上升趋势,正逐步成为影响中老年男性健康的重要疾病,高危前列腺癌是一种具有至少一种高危因素,存在较高转移风险和较差预后的前列腺癌类型,有研究指出10年内死于前列腺癌的患者中有66%来自高危前列腺癌。关于高危前列腺癌的治疗,围手术期进行新辅助治疗和辅助治疗的价值和意义存在争议。本共识采用循证医学方法,查阅和整理评估大量相关文献,进行质量等级评价、证据综合,编写初稿后,通过专家会议讨论、德尔菲问卷调查等方法,经过2轮逾33个不同城市、71家医院共计78名专家意见的调查汇总、归纳梳理和总结,依托中国抗癌协会男性生殖系统肿瘤专业委员会,形成《高危前列腺癌围手术期综合治疗专家共识(2023年版)》。针对高危前列腺癌围手术期的新辅助治疗和辅助治疗进行探索、讨论,希望为临床医师开展高危前列腺癌患者围手术期的治疗提供指导意见和规范依据。The incidence rate of prostate cancer is showing an upward trend year by year,gradually becoming an important disease affecting the health of middle-aged and elderly men.The high-risk prostate cancer is a type of prostate cancer with at least one high-risk factor,which has a higher risk of metastasis and a poorer prognosis.Studies have indicated that 66%of patients who die from prostate cancer within 10 years are having high-risk prostate cancer.There is controversy regarding the value and significance of neoadjuvant and adjuvant therapy during the perioperative period for high-risk prostate cancer treatment.The consensus adopted the evidence-based medical method,extensively reviewed and organized relevant literature,conducted quality grade evaluations and evidence synthesis.After drafting the initial version,expert meetings and Delphi questionnaire surveys were conducted.After two rounds of surveys collecting opinions from 78 experts across 33 different cities and 71 hospitals,the data were summarized and refined.Relying on Society of Male Reproductive System Oncology,China Anti-Cancer Association for the“expert consensus on perioperative comprehensive treatment for high-risk prostate cancer(2023 edition)”was formulated.The aim was to explore and discuss neoadjuvant and adjuvant treatments for high-risk prostate cancer during the perioperative period,hoping to provide clinical doctors with guidance and standardized criteria for treating perioperative patients with high-risk prostate cancer.

关 键 词：高危前列腺癌 围手术期 新辅助治疗 辅助治疗 专家共识 

分 类 号：R737.25[医药卫生—肿瘤]